Table 1.
HPV16 E6 patient profile, clinical and immunological outcome
| Pt | Age | Path | HPV type | Disease extension | # Vac | Off-Study response/reason | PFS (ms) | OS (ms) | Cr-51 | ELISPOT | IR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1A | 39 | ACA | 18 | Mets | 8 | PD | 8.0 | 20.1 | - | + | + |
| 2A | 46 | SCC | 16 | Mets | 1 | SD/PPS | 0.7+ | 1.4 | ND | ND | ND |
| 3A | 41 | SCC | 18 | Mets | 6 | PD | 5.9 | 18.6 | - | - | - |
| 4A | 37 | SCC | 18 | Mets | 4 | PD | 3.6 | 9.7 | - | + | + |
| 5A | 47 | SCC | 18 | Mets | 2 | SD/PPS | 2.8+ | 4.9 | - | - | - |
| 6A | 36 | ASCC | 16 | Mets | 3 | PD | 1.6 | 8.7 | + | NA | + |
| 7A | 40 | ASCC | 18 | Mets | 4 | PD | 4.6 | 6.0 | - | - | - |
| 8A | 48 | ACA | 18 | Mets | 4 | PD | 3.4 | 10.0 | - | NA | - |
| 9A | 40 | SCC | 18 | Mets | 1 | SD/PPS | 4.4+ | 5.2 | ND | ND | ND |
| 10A | 43 | SCC | 18 | Mets | 2 | PD | 1.4 | 4.3 | - | + | + |
| 11A | 44 | ACA | 18 | Mets | 2 | PD | 1.5 | 4.9 | + | - | + |
| 12A | 53 | SCC | 18 | Mets | 2 | PD | 1.6 | 11.1 | - | + | + |
| 13A | 36 | SCC | 18 | Mets | 6 | PD | 5.6 | 10.7 | - | + | + |
| 14A | 36 | SCC | 18 | NED | 6 | PD | 5.3 | 20.5 | NA | - | - |
| 15A | 38 | SCC | 18 | NED | 10 | NED | 67.1+ | 67.1+ | - | + | + |
| 16A | 36 | SCC | 18 | Mets | 14 | SD | 115.9+ | 115.9+ | NA | + | + |
| 17A | 34 | SCC | 16 | Mets | 4 | PD | 0.4 | 3.9 | NA | + | + |
| 18A | 41 | SCC | 16 | Mets | 3 | PD | 1.5 | 3.7 | NA | - | - |
Abbreviations: Pt Patient, Path Pathology, #Vac number of administered vaccines, IR Immune Response, ND Not done, NA Not available, Cr-51 Chromium-51 release assay, ELISPOT Enzyme-Linked ImmunoSpot, SCC Squamous Cell Carcinoma, ACA Adenocarcinoma, ASCC Adenosquamous Carcinoma, NED No Evidence of Disease. PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, Mets metastatic disease, PFS Progression Free Survival, OS Overall Survival, ms Months.